Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, randomized crossover study being conducted in three
cohorts of healthy adult subjects. Approximately 36 subjects will be randomized to one of
three cohorts (approximately 12 subjects per cohort) and they will receive both a single dose
of E2006 in capsule formulation and a single dose of E2006 in tablet formulation, in random
sequence, at a 1:1 ratio. The doses to be tested will be 2.5 mg, 10 mg, and 25 mg.